Fresenius Medical Care AG & Co. (FMS) Announces Earnings Results

Share on StockTwits

Fresenius Medical Care AG & Co. (NYSE:FMS) announced its quarterly earnings data on Thursday. The company reported $0.59 EPS for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07, Morningstar.com reports. Fresenius Medical Care AG & Co. had a return on equity of 10.14% and a net margin of 12.00%. The firm had revenue of $4.13 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period last year, the company posted $0.91 EPS. The business’s quarterly revenue was up 3.9% compared to the same quarter last year.

Shares of Fresenius Medical Care AG & Co. stock traded up $0.55 during trading on Friday, hitting $42.75. 211,791 shares of the stock traded hands, compared to its average volume of 245,187. The firm has a market cap of $25.89 billion, a price-to-earnings ratio of 18.83, a P/E/G ratio of 2.76 and a beta of 1.40. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.25 and a quick ratio of 1.02. Fresenius Medical Care AG & Co. has a twelve month low of $30.99 and a twelve month high of $53.40.

Institutional investors have recently made changes to their positions in the company. Osborn Williams & Donohoe LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. during the 1st quarter valued at about $42,000. Magellan Asset Management Ltd raised its stake in shares of Fresenius Medical Care AG & Co. by 52.3% in the 4th quarter. Magellan Asset Management Ltd now owns 1,433 shares of the company’s stock valued at $46,000 after acquiring an additional 492 shares in the last quarter. Rehmann Capital Advisory Group raised its stake in shares of Fresenius Medical Care AG & Co. by 33.4% in the 4th quarter. Rehmann Capital Advisory Group now owns 1,748 shares of the company’s stock valued at $57,000 after acquiring an additional 438 shares in the last quarter. QS Investors LLC bought a new position in shares of Fresenius Medical Care AG & Co. in the 4th quarter valued at approximately $58,000. Finally, Moloney Securities Asset Management LLC bought a new position in shares of Fresenius Medical Care AG & Co. in the 1st quarter valued at approximately $206,000. Institutional investors and hedge funds own 1.88% of the company’s stock.

A number of equities research analysts have commented on FMS shares. SunTrust Banks raised their price objective on Fresenius Medical Care AG & Co. to $48.00 and gave the stock a “positive” rating in a research report on Thursday, February 21st. DZ Bank restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, March 5th. Royal Bank of Canada restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, March 18th. Finally, Zacks Investment Research upgraded Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating in a research report on Tuesday, February 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Fresenius Medical Care AG & Co. has a consensus rating of “Hold” and an average target price of $65.00.

COPYRIGHT VIOLATION NOTICE: “Fresenius Medical Care AG & Co. (FMS) Announces Earnings Results” was first published by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://weekherald.com/2019/05/04/fresenius-medical-care-ag-co-fms-announces-earnings-results.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Trading Options- What is a Strangle?

Earnings History for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.